Disclosures: Chun-Ming Hong: Nothing to Disclose, Chih-Horng Wu: Nothing to Disclose, Tung-Hung Su: Nothing to Disclose, Shih-Jer Hsu: Nothing to Disclose, Tai-Chung Tseng: Nothing to Disclose, Chen-Hua Liu: Nothing to Disclose, Hung-Chih Yang: Nothing to Disclose, Jia-Horng Kao: Nothing to Disclose, Pei-Jer Chen: Nothing to Disclose, Shang-Chin Huang: Nothing to Disclose, Chun Jen Liu: Nothing to Disclose 1793 RESVERATROL AND TANSHINONE IIA SYNERGIZE TO SUPPRESS HEPATOCELLULAR CARCINOMA BY MODULATING STROMAL CELLS TO REMODEL TUMOR MICROENVIRONMENT Jia Shi 1 Xuemei Zhang 1 Xiaona Lu 1 Shihan Yu 1 Wenlan Zheng 1 Hai Feng 1 Zhuo Yu 2 , 1 Shuguang hospital Affiliated to SHUTCM, 2 Shuguang Hospital Affiliated to Shanghai University of TCM Background: Hepatocellular carcinoma (HCC) is usually insensitive to immunotherapy due to the aggravated immunosuppressive statue in context of liver fibrosis
a further aspect of the invention pertains to treating an NNMT-expressing cancer, such as glioblastoma, by administering a therapeutically effective amount of one or more cations chosen from Tables 3a and 3b followed by the administration of one or more cations of the invention
Additionally, LET7(H290N) purified from Escherichia coli reduced the PPase activity in dephosphorylating p- nitrophenyl phosphate ( p NPP) in an in vitro phosphatase activity, compared with LET7 (Fig
interventions to attenuate vascular calcification progression in chronic kidney disease: a systematic review of clinical trials
